Clinical Trial

Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will enroll patients with HPV-associated oropharyngeal cancer, undergoing resection of all gross visible disease at the primary site and in the lymph nodes. A total of 40 patients who have had or will require surgery to remove cancer cells prior to starting chemoradiation may be enrolled. All eligible patients will receive de-intensified cisplatin-based chemoradiation, with high-risk patients receiving a higher dose and longer treatment period than other patients on the study. The study will assess whether a de-intensified version of standard chemoradiation treatment will be just as effective in treating HPV-associated oropharyngeal cancer while causing less side effects than standard dosing.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2020-08-04; most recent amendment 2026-05-05.
Status change: Recruiting → Active, Not Recruiting 2025-02-11
Status change: Active, Not Recruiting → Recruiting 2024-02-02
Status change: Recruiting → Active, Not Recruiting 2023-10-24
Status change: Not Yet Recruiting → Recruiting 2021-02-16
Trial Details
NCT Number NCT04502407
Lead Sponsor Cedars-Sinai Medical Center
Conditions HPV Positive Oropharyngeal Squamous Cell Carcinoma
Enrollment 40 participants
Start Date 2021-02-16
Primary Completion 2026-12-15 (estimated)
Study Completion 2029-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-05